Study Overview: This study aims to find the highest safe dose of a drug called OTS167 for patients with advanced breast cancer, including Triple Negative Breast Cancer (TNBC). OTS167 is taken as a capsule by mouth. The study involves patients whose cancer has returned or does not respond to standard treatments.
Eligibility: Women aged 18 or older with advanced or metastatic breast cancer can participate. Participants must have cancer that cannot be treated with surgery and must have already tried standard treatments. Patients must be able to provide informed consent and agree to use effective birth control during the study.
Exclusions: Pregnant or breastfeeding women, those with uncontrolled brain metastases, or certain blood and heart conditions cannot participate. Patients with other serious infections or those who recently had major surgery or specific treatments are also excluded.
- This study involves taking an oral medication and requires regular visits for monitoring.
- Participants must have a life expectancy of at least 3 months and stable health conditions.
- There may be risks, including potential side effects from the study drug.
How understandable was the trial content above?
Hard to understand
Easy to understand